Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: dr.praveen who wrote (4774)	3/1/2007 2:19:25 PM
From: dr.praveen	Read Replies (2) \| Respond to of 4974

Press Release: Helicos BioSciences Files Registration Statement for Initial Public Offering of Common Stock March 1, 2007 Helicos BioSciences Files Registration Statement for Initial Public Offering of Common Stock CAMBRIDGE, Mass. -- Feb 28, 2007 - Helicos BioSciences Corporation today announced it has filed a registration statement on Form S-1 with the Securities and Exchange Commission for a proposed initial public offering of its common stock. All of the shares to be offered will be sold by the company. The number of shares to be sold in the proposed offering and the offering price have not yet been determined. UBS Investment Bank will be acting as the sole book-running manager for the offering. J.P. Morgan Securities Inc. is acting as a joint lead manager, with Leerink Swann & Company and Pacific Growth Equities, LLC acting as co-managers. A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. This offering will be made only by means of a prospectus. A copy of the prospectus, when available, may be obtained from the prospectus department of UBS Investment Bank, Attn: Prospectus Department, 299 Park Avenue, New York, NY 10171 (212-821-3000). About Helicos BioSciences Helicos BioSciences Corporation is a life sciences company developing innovative genetic analysis technologies for the research, drug discovery and clinical diagnostics markets. The company has developed its proprietary True Single Molecule Sequencing technology to enable ultra-high-throughput genetic analysis based on the direct sequencing of single molecules of DNA or single copies of RNA. The company's corporate headquarters are located at One Kendall Square, Building 700, Cambridge, MA 02139, and its telephone number is (617) 264-1800.